Hoth said that its legacy biotechnology programs will continue under a wholly owned subsidiary. The company said its shares will begin trading under a new ticker symbol, RKTO, from May 28. Hoth ...

Hoth Therapeutics (NASDAQ:HOTH) shares rose by a staggering 215% today following significant breakthrough in cancer treatment. Their Phase 2a clinical trial of Hoth's topical gel HT-001 has shown 100% ...

Hoth Therapeutics HOTH shares are trading sharply higher in after-hours trading Tuesday. HOTH shares surged 27.94% to $1.74 ...

In the open-label PK cohort, 100% of evaluable patients achieved clinical response by Week 6, accompanied by an approximate 50% reduction in investigator-assessed disease severity (using the ARIGA ...

Patients will be able to enroll in trial at any time and regardless of failure from other therapeutics This is a randomized, double-blind, placebo-controlled, multi-center Phase 2a dose-ranging study ...

NEW YORK, Sept. 13, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a definitive agreement for the purchase ...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Hoth Therapeutics HOTH is a clinical-stage ...

Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a ...